Laden... Bitte warten
Company profile
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure.
Revenues from its growing commercial business help fuel the continued advancement of Valneva’s vaccine pipeline. This includes the world’s first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Source:
Cofisem
-
Last Update:
26 Mar 2025
Key Executives
| Chief Executive Officer | Thomas Lingelbach | ||||
| Deputy CEO | Peter Bühler | ||||
| Chief Financial Officer | Peter Bühler | ||||
| Deputy CEO | Franck Grimaud | ||||
| Chief Business Officer | Franck Grimaud | ||||
| Deputy CEO | Juan Carlos Jaramillo | ||||
| Deputy CEO | Dipal Patel | ||||
| Chief Commercial Officer | Dipal Patel | ||||
| Chief Operating Officer | Vincent Dequenne | ||||
| Chief Human Resources Officer | Petra Pesendorfer | ||||
| Chief Scientific Officer | Hanneke Schuitemaker | ||||
| General Counsel | Kendra Wergin | ||||
| Company Secretary | Kendra Wergin | ||||
| Source: Cofisem - Last Update: 26 Mar 2025 | |||||
Key figures
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 169.579 | 153.713 | 361.303 | 348.086 | 110.321 |
| Income from ordinary activities | 169.579 | 153.713 | 361.303 | 348.086 | 110.321 |
| Operating income | 13.330 | -82.087 | -113.443 | -61.390 | -55.120 |
| Cost of financial indebtedness net | 21.622 | 22.115 | 18.794 | 16.715 | 10.619 |
| Equity-accounted companies contribution to income | 0 | 9 | -5 | -133 | |
| Net profit from discontinued activities | |||||
| Net income | -12.247 | -101.429 | -143.279 | -73.425 | -64.393 |
| Net income (Group share) | -12.247 | -101.429 | -143.279 | -73.425 | -64.393 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
| Source: Cofisem - Last Update: 26 Mar 2025 | |||||
Shareholder information
Adresse
Valneva
6 Rue Alain Bombard
FR-44800
Saint-Herblain
France
Telefonnummer:
+33 (0)2 28 07 37 10
Source:
Cofisem
-
Last Update:
26 Mar 2025
Kontakt
Laetitia Bachelot-Fontaine
Telefonnummer: + 33 (0) 2 28 07 37 10
Source: Valneva - Last Update: 26 Mar 2025